Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183800
Pulmonary hypertension in chronic obstructive pulmonary disease
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Even mild pulmonary hypertension (PH) is associated with increased mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, the underlying mechanisms remain elusive; therefore, specific and efficient treatment options are not available. Therapeutic approaches tested in the clinical setting, including long-term oxygen administration and systemic vasodilators, gave disappointing results and might be only beneficial for specific subgroups of patients. Preclinical studies identified several therapeutic approaches for the treatment of PH in COPD. Further research should provide deeper insight into the complex pathophysiological mechanisms driving vascular alterations in COPD, especially as such vascular (molecular) alterations have been previously suggested to affect COPD development. This review summarizes the current understanding of the pathophysiology of PH in COPD and gives an overview of the available treatment options and recent advances in preclinical studies.
Subject (English)
Citation
Citation
GREDIC, Marija, et al. Pulmonary hypertension in chronic obstructive pulmonary disease. British Journal of Pharmacology. 2019. Vol. 178, num. 1, pags. 132-151. ISSN 0007-1188. [consulted: 13 of June of 2026]. Available at: https://hdl.handle.net/2445/183800